Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Benoxaprofen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | CASP3 | P42574 | 5/20 | 0.58 |
| ▸ | SENP7 | Q9BQF6 | 4/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 7/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benoxaprofen SCHEMBL29364205 | 1.00 | MAOA (1.00) | MAOAADRA1ACASP3SENP7HDAC3 | |
| Benoxaprofen SCHEMBL24414 | 1.00 | MAOA (1.00) | MAOAADRA1ACASP3SENP7HDAC3 | |
| Benoxaprofen SCHEMBL11246423 | 0.99 | MAOA (0.98) | MAOAADRA1ACASP3SENP7HDAC3 | |
| Benoxaprofen SCHEMBL28038058 | 0.99 | MAOA (0.98) | MAOAADRA1ACASP3SENP7HDAC3 | |
| SCHEMBL12608959 | 0.93 | MAOA (0.86) | MAOAADRA1ACASP3SENP7HDAC3 | |
| SCHEMBL3196762 | 0.90 | MAOA (0.82) | MAOAADRA1ACASP3SENP7HDAC3 | |
| SCHEMBL11176670 | 0.90 | MAOA (0.82) | MAOAADRA1ACASP3SENP7HDAC3 | |
| Benoxaprofen SCHEMBL6694507 | 0.89 | MAOA (0.80) | MAOAADRA1ACASP3SENP7HDAC6 | |
| SCHEMBL9706321 | 0.88 | MAOA (0.79) | MAOAADRA1ACASP3SENP7HDAC3 | |
| Benoxaprofen SCHEMBL7925364 | 0.88 | MAOA (0.77) | MAOAADRA1ACASP3SENP7MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 18129 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4628080-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF DRUG-RELATED PEPTIC ULCER COMPRISING ZASTAPRAZAN OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Jeil Pharmaceutical Co., Ltd. (KR) | 2025-10-08 | — | — | EP | claimed |
| EP-4525870-A1 | METHODS OF TREATING CUSHING'S SYNDROME AND LIVER DISORDERS, AND OF REDUCING LIVER TOXICITY OF OTHER DRUGS ADMINISTERED TO A PATIENT | Corcept Therapeutics Incorporated (US) | 2025-03-26 | — | — | EP | claimed |
| US-20250041208-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2025-02-06 | — | — | US | claimed |
| CN-119317433-A | Methods for treating cushing's syndrome and liver disease and reducing hepatotoxicity of other drugs taken by patients | 科赛普特治疗学股份有限公司 | 2025-01-14 | — | — | CN | claimed |
| US-12161726-B2 | Biomimetic vesicles and uses thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2024-12-10 | — | — | US | claimed |
| EP-4470565-A1 | METHOD FOR PREVENTING OR TREATING DISEASE OR DISORDER ASSOCIATED WITH ANTINEOPLASTIC AGENT | OnQuality Pharmaceuticals China Ltd. (CN) | 2024-12-04 | — | — | EP | claimed |
| US-RE50218-E1 | Non-steroidal anti-inflammatory ophthalmic compositions | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2024-11-26 | — | — | US | claimed |
| EP-3706762-B1 | N4-HYDROXYCYTIDINE DERIVATIVE AND ANTI-VIRAL USES RELATED THERETO | UNIV EMORY (US) | 2024-10-16 | — | — | EP | claimed |
| EP-4444277-A1 | NEW INJECTABLE COMBINATION FORMULATION | Nanexa AB (SE) | 2024-10-16 | — | — | EP | claimed |
| EP-4442241-A2 | RETINOL REPLACEMENT IN SKIN TREATMENT | Symrise AG (DE) | 2024-10-09 | — | — | EP | claimed |
| US-4522826-A | SYNERGISTIC MIXTURES | RICHARDSON-VICKS INC. (US) | 1985-06-11 | — | — | US | claimed |
| US-4486436-A | Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same | ANALGESIC ASSOCIATES (US) | 1984-12-04 | — | — | US | claimed |
| US-4472420-A | BENZOXAPROFEN | METHODIST HOSPITAL OF INDIANA, INC. (US) | 1984-09-18 | — | — | US | claimed |
| EP-0114886-A1 | IMPROVED ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING CAFFEINE. | SUNSHINE ABRAHAM (US) | 1984-08-08 | — | — | EP | claimed |
| WO-1984000490-A1 | IMPROVED ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING CAFFEINE AND METHODS OF USING SAME | SUNSHINE ABRAHAM | 1984-02-16 | — | — | WO | claimed |
| US-4416892-A | ANTIALLERGENS | LILLY INDUSTRIES LIMITED (GB) | 1983-11-22 | — | — | US | claimed |
| EP-0072462-A2 | Pharmaceutical preparations | Toko Yakuhin Industry Co., Ltd. (JP) | 1983-02-23 | — | — | EP | claimed |
| US-4355029-A | BENOXAPROFEN AND ASPIRIN | ELI LILLY AND COMPANY (US) | 1982-10-19 | — | — | US | claimed |
| EP-0000276-B1 | A NOVEL CRYSTALLINE FORM OF BENOXAPROFEN, METHODS OF PREPARATION THEREOF AND PHARMACEUTICAL FORMULATIONS CONTAINING SAID NOVEL FORM | Lilly Industries Limited (GB) | 1982-09-01 | — | — | EP | claimed |
| EP-0000276-A1 | A novel crystalline form of benoxaprofen, methods of preparation thereof and pharmaceutical formulations containing said novel form | Lilly Industries Limited (GB) | 1979-01-10 | — | — | EP | claimed |